Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study
Objectives: To identify a candidate set of biomarkers specific to AxPsA. Overview: Clinical and imaging characterization of PsA patients will be combined with extensive molecular assessment of both liquid and tissue compartments to identify biomarkers which differentiate PsA patients with and without axial involvement
Inclusion Criteria:
Persons with PsA diagnosed by a consultant Rheumatologist with disease duration of > 3 months but < 10 years with or without IBP.
Adults between the ages 18 and 80 years, with joint disease onset after 16 years of age
Patients able to understand and complete consent procedures
Study participants must have PsA, meet CASPAR criteria, and must have active disease as defined by the treating rheumatologist, including an evaluable psoriatic skin lesion amenable to 6mm punch skin biopsy.
o Psoriasis should be diagnosed by a consultant rheumatologist or dermatologist.
Study participants must have been on consistent therapy for their PsA for the past 90 days
Study participants must be naïve to biological treatment and targeted synthetic DMARD treatment (examples: JAK inhibitors, apremilast)
Exclusion Criteria:
• Persons with musculoskeletal (peripheral or axial) symptoms for >10 years